Gemcitabine and cisplatin as neo-adjuvant chemotherapy for non-small cell lung cancer: a phase II study.

Lung Cancer 2007 Nov 1;58(2):246-52. Epub 2007 Aug 1.

Istanbul University, Institute of Oncology, Capa 34390, Istanbul, Turkey.

The combination of gemcitabine and cisplatin is one of the most active chemotherapy regimens against non-small cell lung cancer (NSCLC). This study was designed to evaluate the efficacy and safety of gemcitabine combined with cisplatin in a 3-week cycle regimen for patients with operable, early stage NSCLC. Gemcitabine at a dose of 1000 mg/m(2) on days 1 and 8 of each 21-day cycle for 3 cycles, followed by cisplatin at a dose of 75 mg/m(2) on day 1 was administered to patients with previously untreated, operable, early stage (IB-IIIA) NSCLC. A total of 47 patients (46 male, mean age 56.0+/-8.0 years) who met the eligibility criteria were enrolled. The pathological complete response rate was 5.3% of operated patients and 4.3% of total patients. At visit 4, 57.1% of the patients had partial response, 38.1%, stable disease and 4.8%, progressive disease. The main toxicities - leukopenia, neutropenia and thrombocytopenia - were usually clinically asymptomatic and did not require hospitalization. Non-hematological toxicities were minimal and manageable. Disease free and 12-month overall survival rates were over 70% and 80%, respectively. This study demonstrates that the administration of gemcitabine and cisplatin combination for 3 cycles is effective and tolerable for patients with operable, early stage NSCLC. Low toxicity profile and promising survival outcome suggest that this regimen has an encouraging activity in this subset of patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2007.06.006DOI Listing
November 2007
11 Reads

Publication Analysis

Top Keywords

operable early
12
early stage
12
gemcitabine cisplatin
12
non-small cell
8
lung cancer
8
patients operable
8
stage nsclc
8
patients
8
cell lung
8
total patients
8
gemcitabine
5
disease main
4
progressive disease
4
571% patients
4
visit 571%
4
patients visit
4
patients partial
4
48% progressive
4
disease 48%
4
response 381%
4

Similar Publications